Clincosm LogoSign in Get a demo

A Study of Preferences for the First-Line Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer

Sponsor
Bristol-Myers Squibb (Industry)
Overall Status
Recruiting
CT.gov ID
NCT05250817
Collaborator
(none)
650
Enrollment
1
Location
6.7
Anticipated Duration (Months)
97.5
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this observational study is to determine participants' preferences for outcomes associated with first-line treatment of advanced/metastatic Non-Small Cell Lung Cancer (NSCLC) using a discrete-choice experiment (DCE).

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    650 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Preferences for the First-Line Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer
    Actual Study Start Date :
    Dec 9, 2021
    Anticipated Primary Completion Date :
    Jun 30, 2022
    Anticipated Study Completion Date :
    Jun 30, 2022

    Arms and Interventions

    Arm Intervention/Treatment
    Cohort 1

    Participants with early stage and advanced/metastatic non-small cell lung cancer (NSCLC)
    Cohort 2

    Participants from the general population

    Outcome Measures

    Primary Outcome Measures

    1. Set of relative preference weights for all attribute levels included in the Discrete Choice Experiment (DCE) [At Baseline]

    2. Respondents' baseline understanding of attribute descriptions [At Baseline]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    The following is the inclusion criteria for pretest interviews and final online survey.

    Participants:

    • Must be 18 years of age or older

    • Must be a US resident.

    • Lung cancer participants with a physician diagnosis of NSCLC. Global Perspectives will be involved to suggest alternative strategies to a physician-confirmed diagnosis to ensure that actual cancer participants are recruited.

    Exclusion Criteria:
    • Not applicable

    Other protocol-defined inclusion/exclusion criteria apply

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 RTI Health Solutions Research Triangle Park North Carolina United States 27709

    Sponsors and Collaborators

    • Bristol-Myers Squibb

    Investigators

    • Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    Bristol-Myers Squibb
    ClinicalTrials.gov Identifier:
    NCT05250817
    Other Study ID Numbers:
    • CA209-69K
    First Posted:
    Feb 22, 2022
    Last Update Posted:
    Feb 22, 2022
    Last Verified:
    Feb 1, 2022
    Keywords provided by Bristol-Myers Squibb
    Preference
    Advanced/Metastatic NSCLC
    Discrete choice experiment (DCE)
    Additional relevant MeSH terms:
    Carcinoma, Non-Small-Cell Lung

    Study Results

    No Results Posted as of Feb 22, 2022